1. Home
  2. VRNA

as 11-01-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Founded: 2005 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 2.2B IPO Year: 2017
Target Price: $39.33 AVG Volume (30 days): 868.6K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.59 EPS Growth: N/A
52 Week Low/High: $11.39 - $35.62 Next Earning Date: 11-04-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 1077.76%

VRNA Daily Stock ML Predictions

Stock Insider Trading Activity of Verona Pharma plc (VRNA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
ZACCARDELLI DAVID VRNA President and CEO Oct 23 '24 Sell $4.38 144,816 $633,895.84 14,736,536
ZACCARDELLI DAVID VRNA President and CEO Sep 11 '24 Sell $3.76 600,000 $2,254,320.00 14,736,536
EBSWORTH DAVID R VRNA Director Aug 12 '24 Buy $2.87 36,000 $103,320.00 880,643
ZACCARDELLI DAVID VRNA President and CEO Aug 12 '24 Sell $3.19 400,000 $1,280,688.98 14,736,536
Hahn Mark W VRNA Chief Financial Officer Aug 12 '24 Sell $3.19 400,000 $1,280,548.40 14,939,688

Share on Social Networks: